• DOI:10.1007/s40265-018-1002-7
Corpus ID: 53107438

Galcanezumab: First Global Approval

@article{Lamb2018GalcanezumabFG,
  title={Galcanezumab: First Global Approval},
  author={Yvette N. Lamb},
  journal={Drugs},
  year={2018},
  volume={78},
  pages={1769-1775}
}

Yvette N. Lamb

Published 2018

Medicine

Drugs

Galcanezumab-gnlm (Emgality™; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018, the US FDA approved galcanezumab as a once-monthly subcutaneous injection for the preventive treatment of migraine in adults. In the same month, the EMA issued a positive opinion for galcanezumab for the… CONTINUE READING

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed